Literature DB >> 2836712

Differential expression of the major histocompatibility antigen complex (MHC) on a series of Burkitt's lymphoma lines.

T Yokochi1, Y Inoue, H Iwata, T Miyadai, Y Kimura.   

Abstract

We compared the expressions of class I and class II major histocompatibility antigen complex (MHC) on the surface of Jijoye and P3HR-1 cells of Burkitt's lymphoma sublines. Jijoye cells had a large amount of class I and class II MHC antigens, whereas these antigens were less expressed on P3HR-1 cells. On a subline of P3HR-1 K cells the expression of class I antigen markedly diminished and class II antigen was undetectable. On the other hand, Jijoye, P3HR-1, and P3HR-1 K cell lines were confirmed to be Epstein-Barr virus (EBV) nonproducer, low producer, and high producer, respectively. The chemical activation of EBV genome by treating P3HR-1 cells with 12-O-tetradecanoyl phorbol-13 acetate (TPA) and n-butyrate resulted in inhibition of the expression of class I and II antigens, while the addition of retinoic acid, an inhibitor of virus replication, blocked the decrease in the MHC antigen expression. These findings suggested that there might be an inverse correlation between the virus production and the expression of class I and II MHC antigens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2836712      PMCID: PMC7168452          DOI: 10.1111/j.1348-0421.1987.tb01354.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  22 in total

1.  Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV receptor/complement receptor complex in a series of sublines derived from the same original Burkitt's lymphoma.

Authors:  G Klein; E Yefenof; K Falk; A Westman
Journal:  Int J Cancer       Date:  1978-05-15       Impact factor: 7.396

2.  Correlated expression of a B-lymphocyte-specific glycoprotein (gp27/35) and the EBV receptor/C3 receptor complex in sublines from the same Burkitt lymphoma.

Authors:  G Klein; R Hyman; I Trowbridge
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

3.  Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures.

Authors:  Y Hinuma; J T Grace
Journal:  Proc Soc Exp Biol Med       Date:  1967-01

4.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.

Authors:  S Torsteinsdottir; M G Masucci; B Ehlin-Henriksson; C Brautbar; H Ben Bassat; G Klein; E Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

7.  Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line.

Authors:  W King; A L Thomas-Powell; N Raab-Traub; M Hawke; E Kieff
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

8.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells.

Authors:  P I Schrier; R Bernards; R T Vaessen; A Houweling; A J van der Eb
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

10.  Cell surface immunoglobulin. II. Isolation and characterization of immunoglobulin from mouse splenic lymphocytes.

Authors:  E S Vitetta; S Baur; J W Uhr
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.